I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something to compare against.
The bit I cannot resolve on my own is how often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning.
I would rather have one careful answer than five confident ones.
This one has a reasonably settled answer, so here it is. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.
I would rather be corrected than agreed with, if it comes to it.
Dr.AddMedPHL said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
That is correct as far as it goes, and here is where it stops going. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardstammy_FL said:I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something…
Same position here, arrived at the long way round. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.
From the other side of the consultation, briefly.
Blood work came back perfect. baseline bloodwork + this community = winning. 🏆